


Redeye: Iconovo company presentation
Johan Wäborg, CEO of Iconovo, presented what's going on at Iconovo at the Redeye Theme: Medtech & Diagnostics Event 2024. What's going on?
Please…

BIOSTOCK: Inhalationsspecialisterna Iconovo tar in kapital (Swedish only)
En intranasal fetmabehandling under utveckling, en generisk utmanare till astmaprodukten Symbicort och samtal med potentiella partners står på agendan…

Iconovo’s partner Amneal has taken the next important step in the clinical development of ICOres budesonide/formoterol
Iconovo announces that the company's development partner Amneal Pharmaceuticals has completed a clinical pharmacokinetic pilot study comparing ICOres budesonide/formoterol…

Iconovo receives positive guidance from FDA regarding substitutability for ICOpre
Iconovo announces that the US Food and Drug Administration (FDA) has issued a positive guidance regarding the generic substitutability of the company's…

BIOSTOCK: The future of obesity treatment – Iconovo develops intranasal semaglutide
This morning, BIOSTOCK released an article regarding Iconovo's development of an intranasal semaglutide formulation for the treatment of obesity in the…

Iconovo develops intranasally inhaled semaglutide in ICOone Nasal for more user-friendly treatment of overweight and obesity
Iconovo announced today that the company has initiated the development of the GLP-1 analogue semaglutide in the inhaler ICOone Nasal for intranasal treatment…

Systemic Delivery of Biologics via Inhalation: Overcoming Injection Aversion in Modern Therapies
That was the title of the talk by Dr Orest Lastow, CTO at Iconovo, at the meeting New updates in Drug Formulation & Bioavailability organized by Life Science…

Grundaren av Iconovo, Dr Orest Lastow, om att vara sci-fi-författare
Grundaren av Iconovo, Dr Orest Lastow, har blivit intervjuad av Life Science Sweden om sin nya parallella karriär som sci-fi-författare. Orest kombinerar…

EU Business News has awarded Iconovo as the Best Inhalation Therapy Company 2024!
Iconovo is one of the 2024 winners of Scandinavian Business Awards at EU Business News. Iconovo was awarded as Best Inhalation Therapy Company 2024.
…

About Q2-2024 report by CEO Johan Wäborg at Carnegie
Iconovo released the Q2-2024 report today and the CEO at Iconovo, Johan Wäborg was invited to the Carnegie Bank studio to comment and give some more flavor…

Iconovo releases Q2-2024 report
“A quarter of intense business development and constructive negotiations." says Johan Wäborg, CEO at Iconovo.
CEO MESSAGES:
STRATEGIC INITIATIVES…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se